Skip to main content
. Author manuscript; available in PMC: 2018 Oct 4.
Published in final edited form as: J Alzheimers Dis. 2018;64(Suppl 1):S555–S565. doi: 10.3233/JAD-179937

Table 1:

Clinical trials on tau immunotherapy

Tau Epitope Subjects Current Stage Company
Active immunization
AADvac-1 Tau294–305 AD Phase II Axon Neuroscience SE
ACI-35 P-Ser396,404 AD Phase I AC Immune SA - Janssen
Passive immunization
BIIB092
(BMS-986168, IPN007		 Tau8–19 Healthy,
PSP		 Phase I-II Biogen
(Bristol-Meyers Squibb; iPerian)
ABBV-8E12
(CN2–8E12)		 Tau25–30 AD,
PSP		 Phase II AbbVie
(C2N Diagnostics)
RO7105705 P-Ser409? Healthy,
AD		 Phase II AC Immune SA – Genentech - F. Hoffman La Roche AG
LY3303560 Conformational
(7–9, 312–342)		 Healthy,
MCI,
AD		 Phase I Eli Lilly
RG7345, RO6926496 P-Ser422 Healthy Phase I - discontinued F. Hoffman La Roche AG
JNJ-63733657 Middle region Healthy, AD Phase I Janssen
UCB0107 235–246 Healthy Phase I UCB Biopharma

Abbreviations: AD - Alzheimer’s disease; PSP - Progressive supranuclear palsy; MCI - Mild cognitive impairment